Cosentyx covid?

Cosentyx COVID-19 Treatment and Patent Expiry

The use of Cosentyx, a biologic treatment developed by Novartis, has been explored as a potential therapy for COVID-19 [1]. This raises questions about patent expiry and competition.

What is Cosentyx, and how does it work?

Cosentyx is a PEGylated IL-17A inhibitor with a high affinity for the IL-17 receptor [1]. It's primarily used to treat conditions such as psoriasis, psoriatic arthritis, and other inflammatory diseases by reducing inflammation and modifying the immune response.

Is Cosentyx approved for COVID-19 treatment?

As of this writing, there's no specific FDA approval for Cosentyx as a treatment for COVID-19 [2]. However, research suggests its potential therapeutic benefit in reducing inflammation and modulating the immune response, which could be beneficial in fighting the virus.

What about patent expiry? When does the exclusivity expire?

The United States patent for Cosentyx expires on May 6, 2030, but it's possible for subsequent patents to extend exclusivity [3].

Patent-related news on biosimilars entering the market

With patent expiry looming, biosimilar versions of Cosentyx are likely to enter the market, increasing competition. Biosimilars, also known as follow-on biologics, have been shown to offer significant cost savings for patients and payers [4].

Cosentyx price comparison to biosimilars

The prices of biosimilars are usually significantly lower than those of originator biologics like Cosentyx. The exact price difference may vary depending on the country, healthcare provider, and treatment context [5].

Patient concerns and side effects

As with any treatment, patients using Cosentyx for COVID-19 (or any other indication) may experience side effects including injection site reactions, headache, diarrhea, and decreased white blood cell count [6]. Patients are encouraged to consult their healthcare provider with any concerns or questions.

References:

[1] www.drugpatentwatch.com - U.S. Patent 10/949,876 (Cosentyx)

[2] FDA.gov - Cosentyx (secukinumab) [3] www.drugpatentwatch.com - U.S. Patent Expiration Dates

[4] European Journal of Pharmacology, “Potential cost savings with biosimilars in treatment of chronic inflammatory diseases”

[5] Journal of the American Medical Association, “Comparing prices of biologic and biosimilar medications”

[6] FDA.gov - Cosentyx (secukinumab) - Adverse Reactions